IMUX raises €17.5M Series A round
27 September 2016· Mannheim, Germany· manufacturing, energy, robotics, b2b, software_hardware
Initial Series A funding to acquire core drug assets and develop small molecule immune modulators up to clinical proof of concept.
Investors
LeadLife Sciences Partners
Also participating
High-Tech GründerfondsBayern KapitalLifeCare Partners
About IMUX
Stage
Growth
Headquarters
Mannheim, Germany
Founded
2020
Team Size
6–20
Sectors
manufacturingenergyroboticsb2bsoftware_hardware
Source: https://www.imux.com/immunic-successfully-closes-17-5-million-euro-series-a-financing-round/